Kindstar Globalgene Technology, Inc. (HKG:9960)
0.9200
-0.0250 (-2.65%)
Sep 11, 2026, 4:08 PM HKT
HKG:9960 Revenue
Kindstar Globalgene Technology had revenue of 473.62M CNY in the half year ending June 30, 2026, with 0.06% growth. This brings the company's revenue in the last twelve months to 950.26M, up 4.29% year-over-year. In the year 2025, Kindstar Globalgene Technology had annual revenue of 933.57M with 0.65% growth.
Revenue (ttm)
950.26M CNY
Revenue Growth
+4.29%
P/S Ratio
0.86
Revenue / Employee
316.86K CNY
Employees
2,999
Market Cap
940.21M HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 933.57M | 6.00M | 0.65% |
| Dec 31, 2024 | 927.57M | -39.69M | -4.10% |
| Dec 31, 2023 | 967.26M | -419.33M | -30.24% |
| Dec 31, 2022 | 1.39B | 455.92M | 48.99% |
| Dec 31, 2021 | 930.67M | 39.28M | 4.41% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| WuXi XDC Cayman | 8.02B |
| Adicon Holdings | 3.06B |
| Yunkang Group | 624.49M |
| Mega Genomics | 413.73M |
| Biosino Bio-Technology and Science Incorporation | 196.98M |
| Zhong Ji Longevity Science Group | 150.07M |
| King International Investment | 143.23M |
| Guanze Medical Information Industry (Holding) | 98.16M |